Glucocorticoids (especially dexamethasone) reduce mortality of patients with severe and critical COVID-19 with no significant effect on the incidence of adverse reactions (moderate quality). In contrast, glucocorticoids do not benefit patients with mild symptoms (low quality).
Keyphrases
- coronavirus disease
- sars cov
- risk factors
- open label
- magnetic resonance
- quality improvement
- cardiovascular events
- high intensity
- high dose
- respiratory syndrome coronavirus
- clinical trial
- magnetic resonance imaging
- phase iii
- type diabetes
- randomized controlled trial
- coronary artery disease
- cardiovascular disease
- phase ii
- physical activity
- depressive symptoms
- contrast enhanced
- smoking cessation